ArticleInternational journal of molecular sciences2026
Acute and Chronic Toxicity Tests and Assessment of In Vitro and In Vivo Anti-Allergic Effects of Prabchompoothaweep Remedy.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Prabchompoothaweep (PCT) is an anti-allergic remedy on the Thailand National List of Essential Medicines, traditionally used to relieve common colds and allergic reactions in Thai traditional medicine (TTM). However, the anti-allergic activity of PCT and its plant ingredients had not been characterized. We evaluated the acute and chronic oral toxicity of PCT ethanolic extract in rats and assessed its in vitro and in vivo anti-allergic activities. Activity in vitro was measured as inhibition of antigen-induced β-hexosaminidase release in RBL-2H3 cells and in vivo using an ovalbumin (OVA)-induced allergic rhinitis mouse model. The extract produced no mortality or signs of toxicity in either study. Several plant ingredients and the PCT extract inhibited β-hexosaminidase release more effectively than chlorpheniramine. In OVA-induced mice, PCT (75, 150, and 300 mg/kg) did not significantly lower OVA-specific serum IgE or IgG2a (OVA-specific IgG1 was likewise not reduced); however, it reduced inflammatory cell infiltration, goblet cell hyperplasia and mast cell numbers in the nasal mucosa and downregulated the T helper 2 (Th2) cytokines IL-5 and IL-13. These findings support the traditional anti-allergic use of the PCT remedy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.